Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -22.62% and -57.71%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?